"Betty" is a cutting-edge machine able to keep human livers alive outside the body for up to five days. Dr. Quin discusses reprogramming donor organs using RNA medicine to address liver diseases and the potential for transforming organ transplantation. Dr. Quin Wills emphasizes the urgency of addressing chronic diseases of aging, proposes a new approach to drug development using AI and human models, and envisions a future where organs are preserved and therapies are rapidly tested, offering hope for millions of lives.
Dr. Quin has a background as an MD, and additional degrees in genetics, mathematics, and computational biology. Holding doctorates from prestigious institutions like Oxford and Cambridge Universities, the South African Dr. notably founded his first liver drug genomics company 15 years ago. By combining his medical expertise with computational biology, Dr. Quin’s company paved the way for groundbreaking discoveries in liver research and therapeutics. The insights gained from their work not only advanced the understanding of liver diseases but also laid the foundation for more effective, personalized, targeted treatments and improved patient outcomes. At the moment, Dr. Quin Wills is the co-founder and CSO of Ochre Bio.
He is aware for inclusivity and equitable healthcare for all individuals, namely LGBTQ+ communities, who face unique health challenges and disparities which can be exacerbated by the lack of representation and understanding within the biopharmaceutical industry. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at www.ted.com/tedx
5 сен 2024
